24 hours
7 days a week
  • 888-584-0411
  • http://seegerweiss.wpengine.com/wp-content/uploads/fda-logo.jpg

    FDA Delays Decision on Actos Replacement

    By: Seeger Weiss LLP on May 3, 2012

    Last week, Japan-based Takeda Pharmaceutical Co Ltd, makers of the drug Actos, announced that the FDA will extend its review of the company’s drug alogliptin.

    Last week, Japan-based Takeda Pharmaceutical Co Ltd, makers of the drug Actos, announced that the FDA will extend its review of the company’s drug alogliptin. Alogliptin, a diabetes medication, was expected to be the successor to Takeda’s top-selling drug Actos. Before Takeda lost its patent protection on Actos, the type-2 diabetes treatment had been linked to an increased risk of bladder cancer in studies. In response, the FDA issued a warning to doctors who prescribed Actos to patients.

    Seeger Weiss LLP, a national plaintiffs’ law firm, has been actively investigating the link between Actos and bladder cancer. If you believe you or someone you know developed bladder cancer as a result of taking Actos, the firm’s drug injury practice will review your case for free. Contact them here.

    Free Case Evaluation Fill out the form for a Free Case Evaluation within 24 hours

    By submitting this form I agree to the terms of SeegerWeiss.com Disclaimer and Privacy Policy

    Handling Cases NationWide

    we support

    Sign Up to our Consumer Alerts Newletter
    Free Case Evaluation Fill out the form for a Free Case Evaluation within 24 hours

    By submitting this form I agree to the terms of SeegerWeiss.com Disclaimer and Privacy Policy

    ×